Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06371404 · ClinicalTrials.gov registry record
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
A clinical trial of Post Traumatic Stress Disorder and Alcohol Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT06371404: Recruiting study of Post Traumatic Stress Disorder and Alcohol Use Disorder, sponsored by Yale University.
NCT06371404 is a study of Post Traumatic Stress Disorder and Alcohol Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 150 participants, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06371404, a study of Post Traumatic Stress Disorder and Alcohol Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these disorders. This study will examine relationships between HDAC6 and clinical variables of interest. Findings could direct treatment development.
Conditions Studied
Interventions
- DRUG Bavarostat
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2031-06-01 |
What NCT06371404 shows while recruiting
NCT06371404 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 1 intervention - of which Bavarostat is the first listed.
NCT06371404 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06371404 about?
NCT06371404 is a clinical study titled "Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat". The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurre...
What is the current status of trial NCT06371404?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-06-05. Estimated completion is 2031-06-01.
What conditions does trial NCT06371404 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Alcohol Use Disorder.
What interventions are being tested in trial NCT06371404?
The interventions under investigation include: Bavarostat (DRUG).
Who is sponsoring clinical trial NCT06371404?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06371404 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06371404's enrollment target sits among peer trials
150 77th of 262 higher than 184 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
RECRUITING · Phase 2
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Targeting the Default Mode Network: A TMS-fMRI Study
RECRUITING · NA
-
The Effects of Very Brief Exposure on PTSD in U.S. Combat Veterans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI